Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry

April J. Ho, Xue Hua, Suh Lee, Alex D. Leow, Igor Yanovsky, Boris Gutman, Ivo D. Dinov, Natasha Leporé, Jason L. Stein, Arthur W. Toga, Clifford R Jr. Jack, Matthew A Bernstein, Eric M. Reiman, Danielle J. Harvey, John Kornak, Norbert Schuff, Gene E. Alexander, Michael W. Weiner, Paul M. Thompson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

A key question in designing MRI-based clinical trials is how the main magnetic field strength of the scanner affects the power to detect disease effects. In 110 subjects scanned longitudinally at both 3.0 and 1.5 T, including 24 patients with Alzheimer's Disease (AD) [74.8 ± 9.2 years, MMSE: 22.6 ± 2.0 at baseline], 51 individuals with mild cognitive impairment (MCI) [74.1 ± 8.0 years, MMSE: 26.6 ± 2.0], and 35 controls [75.9 ± 4.6 years, MMSE: 29.3 ± 0.8], we assessed whether higher-field MR imaging offers higher or lower power to detect longitudinal changes in the brain, using tensor-based morphometry (TBM) to reveal the location of progressive atrophy. As expected, at both field strengths, progressive atrophy was widespread in AD and more spatially restricted in MCI. Power analysis revealed that, to detect a 25% slowing of atrophy (with 80% power), 37 AD and 108 MCI subjects would be needed at 1.5 T versus 49 AD and 166 MCI subjects at 3 T; however, the increased power at 1.5 T was not statistically significant (α = 0.05) either for TBM, or for SIENA, a related method for computing volume loss rates. Analysis of cumulative distribution functions and false discovery rates showed that, at both field strengths, temporal lobe atrophy rates were correlated with interval decline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), mini-mental status exam (MMSE), and Clinical Dementia Rating sum-of-boxes (CDR-SB) scores. Overall, 1.5 and 3 T scans did not significantly differ in their power to detect neurodegenerative changes over a year.

Original languageEnglish (US)
Pages (from-to)499-514
Number of pages16
JournalHuman Brain Mapping
Volume31
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Disease Progression
Alzheimer Disease
Atrophy
Temporal Lobe
Magnetic Fields
Dementia
Power (Psychology)
Clinical Trials
Cognitive Dysfunction
Brain

Keywords

  • Alzheimer's disease
  • Field strength
  • MRI
  • Tensor-based morphometry

ASJC Scopus subject areas

  • Clinical Neurology
  • Anatomy
  • Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Ho, A. J., Hua, X., Lee, S., Leow, A. D., Yanovsky, I., Gutman, B., ... Thompson, P. M. (2010). Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Human Brain Mapping, 31(4), 499-514. https://doi.org/10.1002/hbm.20882

Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. / Ho, April J.; Hua, Xue; Lee, Suh; Leow, Alex D.; Yanovsky, Igor; Gutman, Boris; Dinov, Ivo D.; Leporé, Natasha; Stein, Jason L.; Toga, Arthur W.; Jack, Clifford R Jr.; Bernstein, Matthew A; Reiman, Eric M.; Harvey, Danielle J.; Kornak, John; Schuff, Norbert; Alexander, Gene E.; Weiner, Michael W.; Thompson, Paul M.

In: Human Brain Mapping, Vol. 31, No. 4, 04.2010, p. 499-514.

Research output: Contribution to journalArticle

Ho, AJ, Hua, X, Lee, S, Leow, AD, Yanovsky, I, Gutman, B, Dinov, ID, Leporé, N, Stein, JL, Toga, AW, Jack, CRJ, Bernstein, MA, Reiman, EM, Harvey, DJ, Kornak, J, Schuff, N, Alexander, GE, Weiner, MW & Thompson, PM 2010, 'Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry', Human Brain Mapping, vol. 31, no. 4, pp. 499-514. https://doi.org/10.1002/hbm.20882
Ho, April J. ; Hua, Xue ; Lee, Suh ; Leow, Alex D. ; Yanovsky, Igor ; Gutman, Boris ; Dinov, Ivo D. ; Leporé, Natasha ; Stein, Jason L. ; Toga, Arthur W. ; Jack, Clifford R Jr. ; Bernstein, Matthew A ; Reiman, Eric M. ; Harvey, Danielle J. ; Kornak, John ; Schuff, Norbert ; Alexander, Gene E. ; Weiner, Michael W. ; Thompson, Paul M. / Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. In: Human Brain Mapping. 2010 ; Vol. 31, No. 4. pp. 499-514.
@article{e468ca00aa41422d9a0e07c7629a1a44,
title = "Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry",
abstract = "A key question in designing MRI-based clinical trials is how the main magnetic field strength of the scanner affects the power to detect disease effects. In 110 subjects scanned longitudinally at both 3.0 and 1.5 T, including 24 patients with Alzheimer's Disease (AD) [74.8 ± 9.2 years, MMSE: 22.6 ± 2.0 at baseline], 51 individuals with mild cognitive impairment (MCI) [74.1 ± 8.0 years, MMSE: 26.6 ± 2.0], and 35 controls [75.9 ± 4.6 years, MMSE: 29.3 ± 0.8], we assessed whether higher-field MR imaging offers higher or lower power to detect longitudinal changes in the brain, using tensor-based morphometry (TBM) to reveal the location of progressive atrophy. As expected, at both field strengths, progressive atrophy was widespread in AD and more spatially restricted in MCI. Power analysis revealed that, to detect a 25{\%} slowing of atrophy (with 80{\%} power), 37 AD and 108 MCI subjects would be needed at 1.5 T versus 49 AD and 166 MCI subjects at 3 T; however, the increased power at 1.5 T was not statistically significant (α = 0.05) either for TBM, or for SIENA, a related method for computing volume loss rates. Analysis of cumulative distribution functions and false discovery rates showed that, at both field strengths, temporal lobe atrophy rates were correlated with interval decline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), mini-mental status exam (MMSE), and Clinical Dementia Rating sum-of-boxes (CDR-SB) scores. Overall, 1.5 and 3 T scans did not significantly differ in their power to detect neurodegenerative changes over a year.",
keywords = "Alzheimer's disease, Field strength, MRI, Tensor-based morphometry",
author = "Ho, {April J.} and Xue Hua and Suh Lee and Leow, {Alex D.} and Igor Yanovsky and Boris Gutman and Dinov, {Ivo D.} and Natasha Lepor{\'e} and Stein, {Jason L.} and Toga, {Arthur W.} and Jack, {Clifford R Jr.} and Bernstein, {Matthew A} and Reiman, {Eric M.} and Harvey, {Danielle J.} and John Kornak and Norbert Schuff and Alexander, {Gene E.} and Weiner, {Michael W.} and Thompson, {Paul M.}",
year = "2010",
month = "4",
doi = "10.1002/hbm.20882",
language = "English (US)",
volume = "31",
pages = "499--514",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry

AU - Ho, April J.

AU - Hua, Xue

AU - Lee, Suh

AU - Leow, Alex D.

AU - Yanovsky, Igor

AU - Gutman, Boris

AU - Dinov, Ivo D.

AU - Leporé, Natasha

AU - Stein, Jason L.

AU - Toga, Arthur W.

AU - Jack, Clifford R Jr.

AU - Bernstein, Matthew A

AU - Reiman, Eric M.

AU - Harvey, Danielle J.

AU - Kornak, John

AU - Schuff, Norbert

AU - Alexander, Gene E.

AU - Weiner, Michael W.

AU - Thompson, Paul M.

PY - 2010/4

Y1 - 2010/4

N2 - A key question in designing MRI-based clinical trials is how the main magnetic field strength of the scanner affects the power to detect disease effects. In 110 subjects scanned longitudinally at both 3.0 and 1.5 T, including 24 patients with Alzheimer's Disease (AD) [74.8 ± 9.2 years, MMSE: 22.6 ± 2.0 at baseline], 51 individuals with mild cognitive impairment (MCI) [74.1 ± 8.0 years, MMSE: 26.6 ± 2.0], and 35 controls [75.9 ± 4.6 years, MMSE: 29.3 ± 0.8], we assessed whether higher-field MR imaging offers higher or lower power to detect longitudinal changes in the brain, using tensor-based morphometry (TBM) to reveal the location of progressive atrophy. As expected, at both field strengths, progressive atrophy was widespread in AD and more spatially restricted in MCI. Power analysis revealed that, to detect a 25% slowing of atrophy (with 80% power), 37 AD and 108 MCI subjects would be needed at 1.5 T versus 49 AD and 166 MCI subjects at 3 T; however, the increased power at 1.5 T was not statistically significant (α = 0.05) either for TBM, or for SIENA, a related method for computing volume loss rates. Analysis of cumulative distribution functions and false discovery rates showed that, at both field strengths, temporal lobe atrophy rates were correlated with interval decline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), mini-mental status exam (MMSE), and Clinical Dementia Rating sum-of-boxes (CDR-SB) scores. Overall, 1.5 and 3 T scans did not significantly differ in their power to detect neurodegenerative changes over a year.

AB - A key question in designing MRI-based clinical trials is how the main magnetic field strength of the scanner affects the power to detect disease effects. In 110 subjects scanned longitudinally at both 3.0 and 1.5 T, including 24 patients with Alzheimer's Disease (AD) [74.8 ± 9.2 years, MMSE: 22.6 ± 2.0 at baseline], 51 individuals with mild cognitive impairment (MCI) [74.1 ± 8.0 years, MMSE: 26.6 ± 2.0], and 35 controls [75.9 ± 4.6 years, MMSE: 29.3 ± 0.8], we assessed whether higher-field MR imaging offers higher or lower power to detect longitudinal changes in the brain, using tensor-based morphometry (TBM) to reveal the location of progressive atrophy. As expected, at both field strengths, progressive atrophy was widespread in AD and more spatially restricted in MCI. Power analysis revealed that, to detect a 25% slowing of atrophy (with 80% power), 37 AD and 108 MCI subjects would be needed at 1.5 T versus 49 AD and 166 MCI subjects at 3 T; however, the increased power at 1.5 T was not statistically significant (α = 0.05) either for TBM, or for SIENA, a related method for computing volume loss rates. Analysis of cumulative distribution functions and false discovery rates showed that, at both field strengths, temporal lobe atrophy rates were correlated with interval decline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), mini-mental status exam (MMSE), and Clinical Dementia Rating sum-of-boxes (CDR-SB) scores. Overall, 1.5 and 3 T scans did not significantly differ in their power to detect neurodegenerative changes over a year.

KW - Alzheimer's disease

KW - Field strength

KW - MRI

KW - Tensor-based morphometry

UR - http://www.scopus.com/inward/record.url?scp=77949348120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949348120&partnerID=8YFLogxK

U2 - 10.1002/hbm.20882

DO - 10.1002/hbm.20882

M3 - Article

C2 - 19780044

AN - SCOPUS:77949348120

VL - 31

SP - 499

EP - 514

JO - Human Brain Mapping

JF - Human Brain Mapping

SN - 1065-9471

IS - 4

ER -